Ultragenyx Pharmaceutical Q2 2025 Earnings Call Transcript: Financial Results and Business Update

Ultragenyx Pharmaceutical reported Q2 2025 earnings, with CEO Emil Kakkis, CFO Howard Horn, and CMO Eric Crombez participating in the conference call. The company's financial results and press release are available on its website. Participants from Jefferies, Barclays, Baird, and other firms will ask questions during the call.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) reported its second-quarter 2025 financial results, delivering mixed performance relative to analyst expectations. The company’s revenue and earnings per share (EPS) figures, alongside its reaffirmed full-year guidance, provide insight into its current trajectory and market positioning.

Key Financial Highlights
- Revenue Beat: Ultragenyx posted Q2 2025 revenue of $166.5 million, slightly above the consensus estimate of $164.8 million. This represents a modest outperformance of approximately 1%.
- Narrower-than-Expected Loss: The company reported an EPS of -$1.17, better than the anticipated -$1.32, reflecting improved cost management or revenue strength.
- Product Performance: Crysvita®, the company’s leading therapy, generated $120 million, while Dojolvi® contributed $23 million, both in line with internal expectations.

Market Reaction
Following the earnings release, Ultragenyx shares saw an after-hours gain of ~1.94%, suggesting cautious optimism among investors. Over the past month, the stock has declined ~28.1%, but the recent uptick indicates some relief after the earnings beat. Short-term performance (last week and two weeks) shows minor gains of 0.03% and 0.08%, respectively, suggesting muted sentiment prior to the report.

Full-Year and Q3 Outlook
The company reaffirmed its 2025 revenue guidance of $640 million to $670 million, with Crysvita expected to contribute $460 million to $480 million and Dojolvi projected at $90 million to $100 million.

Analysts currently estimate full-year 2025 sales at $665 million, aligning closely with Ultragenyx’s forecast.

For Q3 2025, Wall Street expects revenue of $167.8 million and an EPS of -$1.32, setting a benchmark for the next earnings report.

Press Release Summary
The earnings update primarily emphasized:
- Steady revenue growth driven by Crysvita and Dojolvi.
- Reaffirmation of full-year guidance, signaling confidence in meeting targets.
- No major pipeline updates or unexpected operational developments.

Conclusion
Ultragenyx’s Q2 results reflect a slight revenue beat and a narrower loss than expected, which appears to have tempered some investor concerns. The reaffirmed guidance suggests stability, though the stock’s longer-term downtrend indicates broader market skepticism.

For a deeper dive into Ultragenyx’s earnings and analyst estimates, visit the earnings page.

Disclaimer: This article is not investment advice. Investors should conduct their own research or consult a financial advisor before making decisions.

References:
[1] https://www.chartmill.com/news/RARE/Chartmill-32379-Ultragenyx-Pharmaceutical-Inc-NASDAQRARE-Reports-Mixed-Q2-2025-Earnings-Beats-Revenue-Estimates-and-Narrows-Loss
[2] https://seekingalpha.com/news/4479315-ultragenyx-pharmaceutical-gaap-eps-of-1_17-beats-by-0_13-revenue-of-166_5m-beats-by-5_13m